Addiction clinics see rising cases of kratom and 7-OH withdrawal

Addiction treatment centers report a rising number of patients presenting with dependence on kratom and its concentrated derivative, 7-hydroxymitragynine, known as 7-OH, according to STAT News. The September 21 report describes clinics observing a surge in cases tied to these products, which remain legal in most jurisdictions despite their psychoactive effects.

Kratom, derived from a Southeast Asian tree, has circulated for years as an over-the-counter supplement marketed for pain relief and mood effects. The newer concern centers on 7-OH, a compound found naturally in trace amounts in kratom leaves but now sold in concentrated form, with potency that clinicians say drives more severe withdrawal symptoms than plant-based kratom alone.

STAT News reports that addiction specialists are treating patients who developed dependence after using these products, often purchased without prescription or medical oversight. The report does not specify total case counts or name individual clinics beyond describing a general pattern observed across treatment settings.

The rise in reported dependence comes as kratom and 7-OH products remain largely unregulated at the federal level in the United States, sold in gas stations, smoke shops, and online retailers. Their legal status has kept them outside the classification systems used for controlled substances, even as clinical reports of withdrawal and dependence accumulate. The Specola’s log records the observation as reported, without further characterization of scope or regulatory response.